Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

Valeriy Domenyuk, Zoran Gatalica, Radhika Santhanam, Xixi Wei, Adam Stark, Patrick Kennedy, B Toussaint, Symon Levenberg, Jie Wang, Nianqing Xiao, Richard Greil, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Amy B. Heimberger, Donald A. Berry, Anna D. Barker, John Quackenbush, John L. Marshall, George Poste, Jeffrey Vacirca, Gregory A. Vidal, Lee S. Schwartzberg, David D. Halbert, Andreas Voß, Daniel Magee, Mark Miglarese, Michael Famulok, Günter Mayer, David SpetzlerNature Communications 2018 · DOI

Abstract

Assessing the phenotypic diversity underlying tumour progression requires the identification of variations in the respective molecular interaction networks. Here we report proof-of-concept for a platform called poly-ligand profiling (PLP) that surveys these system states and distinguishes breast cancer patients who did or did not derive benefit from trastuzumab. We perform tissue-SELEX on breast cancer specimens to enrich single-stranded DNA (ssDNA) libraries that preferentially interact with molecular components associated with the two clinical phenotypes. Testing of independent sample sets verifies the ability of PLP to classify trastuzumab-treated patients according to their clinical outcomes with ROC-AUC of 0.78. Standard HER2 testing of the same patients gives a ROC-AUC of 0.47. Kaplan–Meier analysis reveals a median increase in benefit from trastuzumab-containing treatments of 300 days for PLP-positive compared to PLP-negative patients. If prospectively validated, PLP may increase success rates in precision oncology and clinical trials, thus improving both patient care and drug development.

Introduction

Precision oncology currently operates under a "one target, one drug" paradigm. A primary example is the use of trastuzumab (Herceptin) for breast cancer patients who overexpress the HER2 protein. However, this reductionist model is imperfect: approximately 38–50% of HER2-positive patients fail to derive clinical benefit, while some HER2-negative patients unexpectedly respond.

The authors propose that a tumor’s drug response is governed by its "interactome"—the complex network of molecular interactions and system states—rather than a single protein. Poly-ligand profiling (PLP) was developed to measure these global states without requiring prior knowledge of specific target proteins.

Methods: Tissue-SELEX and Library Enrichment

The core of the PLP platform is tissue-SELEX (Systematic Evolution of Ligands by Exponential Enrichment). This process generates "aptamers"—short, single-stranded DNA (ssDNA) sequences that fold into unique 3D shapes to bind molecular targets within tissue samples.

The tissue-SELEX workflow used to iteratively enrich DNA libraries for sequences that bind specifically to 'Benefit' or 'No Benefit' tumor phenotypes.

Researchers began with a massive random library of $10^{13}$ unique ssDNA sequences. Through iterative rounds of selection using formalin-fixed paraffin-embedded (FFPE) tumor samples, they refined the library into two specialized pools: EL-B (enriched for binding to "Benefit" tissue) and EL-NB (enriched for "No Benefit" tissue). These libraries were then used as histological stains. A pathologist, blinded to patient outcomes, assigned "H-scores" based on binding intensity, which were then processed via a logistic regression model to classify new patients.

Study Design and Datasets

The study utilized three distinct cohorts to train and validate the PLP platform:

  1. Discovery/Enrichment Set: 33 breast cancer cases with known Time to Next Therapy (TTNT) used to train the libraries.
  2. Independent Test Set: 61 trastuzumab-treated patients used to validate predictive accuracy.
  3. Control Set: 63 patients treated with chemotherapy without trastuzumab to determine if the test was specifically predictive of drug response or merely prognostic of general survival.
Flowchart detailing the enrollment and selection process for the discovery, test, and control cohorts.

Key Results

PLP demonstrated a significant improvement over the current clinical standard. In the independent test set, the platform achieved an ROC-AUC of 0.78, whereas standard HER2 immunohistochemistry (IHC) testing on the same samples resulted in an AUC of only 0.47—essentially no better than a coin flip in this metastatic cohort.

Clinical impact was further highlighted by Kaplan–Meier analysis. Patients identified as "PLP-positive" experienced a median benefit of 429 days on trastuzumab-containing treatments, compared to 129 days for "PLP-negative" patients. This 300-day difference represents a substantial clinical improvement in progression-free survival.

Crucially, the PLP test failed to differentiate outcomes in the control group (patients not receiving trastuzumab). This confirms that the platform is measuring a specific molecular state related to the drug's mechanism of action, rather than general patient health.

Discussion and Limitations

PLP offers a "black box" advantage: it identifies relevant molecular differences between responders and non-responders without needing to pre-identify the target proteins. This system-wide view captures the complexity of resistance mechanisms that single-protein biomarkers miss.

However, several hurdles remain before clinical adoption. This was a retrospective study with a relatively small test set (n=61). Prospective clinical trials and larger cohorts are necessary to ensure the model generalizes across diverse breast cancer subtypes. Additionally, identifying the specific molecular targets bound by the EL-B and EL-NB libraries could provide new biological insights into trastuzumab resistance.

Summary updated

Abstract

Abstract Assessing the phenotypic diversity underlying tumour progression requires the identification of variations in the respective molecular interaction networks. Here we report proof-of-concept for a platform called poly-ligand profiling (PLP) that surveys these system states and distinguishes breast cancer patients who did or did not derive benefit from trastuzumab. We perform tissue-SELEX on breast cancer specimens to enrich single-stranded DNA (ssDNA) libraries that preferentially interact with molecular components associated with the two clinical phenotypes. Testing of independent sample sets verifies the ability of PLP to classify trastuzumab-treated patients according to their clinical outcomes with ROC-AUC of 0.78. Standard HER2 testing of the same patients gives a ROC-AUC of 0.47. Kaplan–Meier analysis reveals a median increase in benefit from trastuzumab-containing treatments of 300 days for PLP-positive compared to PLP-negative patients. If prospectively validated, PLP may increase success rates in precision oncology and clinical trials, thus improving both patient care and drug development.
BibTeX
@inproceedings{domenyuk2018poly,
  author = {Valeriy Domenyuk and Zoran Gatalica and Radhika Santhanam and Xixi Wei and Adam Stark and Patrick Kennedy and B Toussaint and Symon Levenberg and Jie Wang and Nianqing Xiao and Richard Greil and Gabriel Rinnerthaler and Simon Peter Gampenrieder and Amy B. Heimberger and Donald A. Berry and Anna D. Barker and John Quackenbush and John L. Marshall and George Poste and Jeffrey Vacirca and Gregory A. Vidal and Lee S. Schwartzberg and David D. Halbert and Andreas Voß and Daniel Magee and Mark Miglarese and Michael Famulok and Günter Mayer and David Spetzler},
  title = {{Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes}},
  booktitle = {Nature Communications},
  year = {2018},
  doi = {10.1038/s41467-018-03631-z},
}
Figure